Funded Tech Companies
Tagworks Pharmaceuticals
Tagworks Pharmaceuticals, operating out of Nijmegen, received investment capital from Novartis Venture Fund, Gilde Healthcare Partners and Meneldor.
Company Overview
Company Name
Tagworks Pharmaceuticals
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Toernooiveld 1
Nijmegen, 6525 ED
NL
Nijmegen, 6525 ED
NL
Phone
Website
Email Address
Company Background Information
Overview
We aim to unlock the full potential of powerful systemic therapies to change the standard of care for patients suffering from severe diseases including cancer. Tagworks Pharmaceuticals was built to resolve the challenges of bringing antibody-drug conjugates (ADCs) and other potent therapies into mainstream cancer treatment. We are the pioneers of the technology known as Click-to-Release, and the first company built to utilize this therapeutic approach. Click-to-Release was developed based on the 2022 Nobel Prize winning research of Carolyn Bertozzi, Morten Meldal and Barry Sharpless, as well as on the foundational work of Joseph Fox (University of Delaware). This technology, centered on the use of a selective chemical (click) reaction in the body to release a payload, enables on-target activation of ADCs, masked Immunomodulators and other prodrugs, as well as off-target deactivation of radioimmunotherapies.
Last Transaction
6/22/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Company Investors
- Novartis Venture Fund (Marianne Uteng)
- Gilde Healthcare Partners (Edwin Graaf)
- Meneldor
- New Enterprise Associates
- National Education Association (Michele Park)
- Oost NL
- Lightstone Ventures (Christina Isacson)
- Ysios Capital (Thomas Harth)
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs